Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04675333 · ClinicalTrials.gov registry record · Phase 2

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

A Phase 2 study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma, sponsored by ALX Oncology.

Active
Registry status
Phase 2
Development phase
172
Enrollment target
20
Study locations

NCT04675333 is a Phase 2 study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma that is active but no longer recruiting, run by ALX Oncology. The registered enrollment target is 172 participants, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (34% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04675333, a Phase 2 study of Head and Neck Cancer and Head and Neck Squamous Cell Carcinoma, is active but no longer recruiting, sponsored by ALX Oncology.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
172 participants
Enrollment target
20
Study locations

Study Summary

A Phase 2 Study of evorpacept (ALX148) in Combination With pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma.

Conditions Studied

Head and Neck Cancer Head and Neck Squamous Cell Carcinoma

Interventions

  • DRUG pembrolizumab
  • DRUG evorpacept
  • DRUG Cisplatin/Carboplatin; 5FU

Study Locations (20)

Other

  • Sir Charles Gairdner Hospital - Nedlands
  • Cliniques Universitaires Saint-Luc - Brussels
  • AZ Groeninge - Kortrijk
  • Amsterdam UMC, Locatie VUMC - Amsterdam

California

  • Hoag Hospital - Irvine
  • University of California San Diego - La Jolla
  • Cedar Sinai Medical Center - Los Angeles

Florida

  • University of Miami, Sylvester Comprehensive Cancer Center - Miami
  • Moffitt Cancer Center - Tampa

Illinois

  • Rush University Medical Center - Chicago

Kentucky

  • University of Louisville - Louisville

Maryland

  • University of Maryland Medical System - Baltimore

New York

  • Memorial Sloan Kettering - New York

Ohio

  • The Ohio State University - Columbus

Trial Details

FieldValue
Enrollment Target 172 participants
Start Date 2021-05-10
Est. Completion 2026-06-30
Phase Phase 2

Sponsor

ALX Oncology

9 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04675333

The ClinicalTrials.gov registry entry for NCT04675333 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 172 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 260-participant average among 250 other Head and Neck Cancer trials with a reported enrollment target (34% lower). The listed sponsor is ALX Oncology, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Head and Neck Cancer appearing as the primary indexed condition, and to 3 interventions - of which pembrolizumab is the first listed.

NCT04675333 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, California, Florida.

Frequently Asked Questions

What is clinical trial NCT04675333 about?

NCT04675333 is a clinical study titled "Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)". A Phase 2 Study of evorpacept (ALX148) in Combination With pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma.

What is the current status of trial NCT04675333?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 172 participants. The study started on 2021-05-10. Estimated completion is 2026-06-30.

What conditions does trial NCT04675333 study?

This clinical trial studies the following conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma.

What interventions are being tested in trial NCT04675333?

The interventions under investigation include: pembrolizumab (DRUG), evorpacept (DRUG), Cisplatin/Carboplatin; 5FU (DRUG).

Who is sponsoring clinical trial NCT04675333?

This trial is sponsored by ALX Oncology, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04675333 being conducted?

This trial has 20 study locations across California, Florida, Illinois, Kentucky, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Head and Neck Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Head and Neck Cancer

All registered trials for this condition

Head and Neck Squamous Cell Carcinoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.